Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Plaque, Atherosclerotic | 78 | 2024 | 1499 | 12.290 |
Why?
|
Coronary Artery Disease | 108 | 2024 | 6454 | 7.640 |
Why?
|
Coronary Vessels | 66 | 2024 | 3099 | 6.420 |
Why?
|
Endothelium, Vascular | 37 | 2023 | 4455 | 4.160 |
Why?
|
Coronary Circulation | 29 | 2022 | 1572 | 4.130 |
Why?
|
Coronary Angiography | 75 | 2024 | 4567 | 3.840 |
Why?
|
Stress, Mechanical | 31 | 2023 | 1684 | 3.590 |
Why?
|
Myocardial Ischemia | 41 | 2023 | 2145 | 3.560 |
Why?
|
Shear Strength | 7 | 2019 | 165 | 2.520 |
Why?
|
Angina Pectoris | 29 | 2023 | 977 | 2.360 |
Why?
|
Electrocardiography, Ambulatory | 35 | 2017 | 585 | 2.270 |
Why?
|
Hemodynamics | 21 | 2023 | 4197 | 1.900 |
Why?
|
Angina, Unstable | 22 | 2022 | 926 | 1.620 |
Why?
|
Ultrasonography, Interventional | 21 | 2024 | 1483 | 1.450 |
Why?
|
Coronary Restenosis | 6 | 2019 | 424 | 1.370 |
Why?
|
Angioplasty, Balloon, Coronary | 16 | 2021 | 1873 | 1.350 |
Why?
|
Coronary Disease | 34 | 2020 | 6078 | 1.300 |
Why?
|
Myocardial Revascularization | 9 | 2022 | 841 | 1.250 |
Why?
|
Stents | 10 | 2021 | 3276 | 1.200 |
Why?
|
Acute Coronary Syndrome | 15 | 2022 | 2337 | 1.190 |
Why?
|
Acetanilides | 5 | 2013 | 168 | 1.180 |
Why?
|
Coronary Stenosis | 10 | 2021 | 834 | 1.180 |
Why?
|
Disease Progression | 45 | 2023 | 13256 | 1.100 |
Why?
|
Atherosclerosis | 13 | 2023 | 3428 | 1.060 |
Why?
|
Exercise Test | 27 | 2017 | 2075 | 1.010 |
Why?
|
Arrhythmias, Cardiac | 9 | 2023 | 2267 | 0.960 |
Why?
|
Models, Cardiovascular | 9 | 2020 | 994 | 0.950 |
Why?
|
Myocardial Infarction | 64 | 2023 | 11690 | 0.930 |
Why?
|
Neointima | 4 | 2016 | 135 | 0.910 |
Why?
|
Predictive Value of Tests | 41 | 2024 | 15056 | 0.900 |
Why?
|
Nifedipine | 15 | 2000 | 226 | 0.870 |
Why?
|
Regional Blood Flow | 6 | 2018 | 1525 | 0.800 |
Why?
|
Piperazines | 5 | 2013 | 2488 | 0.720 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2023 | 3239 | 0.670 |
Why?
|
Electrodes, Implanted | 1 | 2023 | 824 | 0.670 |
Why?
|
Humans | 270 | 2024 | 742088 | 0.650 |
Why?
|
Stress, Physiological | 6 | 2017 | 1402 | 0.630 |
Why?
|
Imaging, Three-Dimensional | 8 | 2020 | 4029 | 0.590 |
Why?
|
Microcirculation | 3 | 2018 | 1285 | 0.590 |
Why?
|
Drug-Eluting Stents | 4 | 2016 | 753 | 0.590 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2020 | 279 | 0.580 |
Why?
|
Heptanoic Acids | 4 | 2007 | 343 | 0.540 |
Why?
|
Arteries | 4 | 2021 | 1118 | 0.530 |
Why?
|
Vasodilator Agents | 6 | 2006 | 976 | 0.510 |
Why?
|
Tomography, Optical Coherence | 9 | 2020 | 2637 | 0.510 |
Why?
|
Heart Rate | 23 | 2011 | 4091 | 0.500 |
Why?
|
Rupture, Spontaneous | 5 | 2020 | 354 | 0.480 |
Why?
|
Vehicle Emissions | 4 | 2007 | 665 | 0.460 |
Why?
|
Adrenergic beta-Antagonists | 14 | 2013 | 1239 | 0.450 |
Why?
|
Hyperplasia | 1 | 2016 | 1183 | 0.450 |
Why?
|
Middle Aged | 139 | 2023 | 213127 | 0.440 |
Why?
|
Male | 158 | 2023 | 349538 | 0.440 |
Why?
|
Procollagen | 1 | 2013 | 185 | 0.430 |
Why?
|
Electrocardiography | 34 | 2011 | 6440 | 0.430 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 3 | 2019 | 1183 | 0.430 |
Why?
|
Endothelium | 1 | 2015 | 778 | 0.430 |
Why?
|
Risk Factors | 55 | 2024 | 72145 | 0.420 |
Why?
|
Matrix Metalloproteinases | 2 | 2013 | 391 | 0.410 |
Why?
|
Cholesterol, LDL | 10 | 2019 | 2354 | 0.410 |
Why?
|
Sodium Channel Blockers | 1 | 2013 | 176 | 0.410 |
Why?
|
Diabetic Angiopathies | 4 | 2018 | 820 | 0.410 |
Why?
|
Aviation | 1 | 2011 | 42 | 0.390 |
Why?
|
Pyrroles | 4 | 2007 | 1143 | 0.390 |
Why?
|
Amlodipine | 4 | 2006 | 83 | 0.390 |
Why?
|
Aged | 103 | 2022 | 162944 | 0.390 |
Why?
|
Sodium Channels | 1 | 2013 | 349 | 0.380 |
Why?
|
Female | 147 | 2023 | 379592 | 0.370 |
Why?
|
Computer Simulation | 6 | 2016 | 6191 | 0.370 |
Why?
|
Allopurinol | 1 | 2011 | 185 | 0.360 |
Why?
|
Collagen Type I | 1 | 2013 | 592 | 0.360 |
Why?
|
Air Pollution | 7 | 2010 | 2284 | 0.360 |
Why?
|
Enzyme Inhibitors | 2 | 2011 | 3800 | 0.360 |
Why?
|
Stress, Psychological | 9 | 2022 | 4229 | 0.350 |
Why?
|
Registries | 23 | 2023 | 8077 | 0.350 |
Why?
|
Blood Flow Velocity | 8 | 2015 | 1423 | 0.340 |
Why?
|
Anticholesteremic Agents | 4 | 2007 | 979 | 0.340 |
Why?
|
Coronary Thrombosis | 3 | 2020 | 494 | 0.340 |
Why?
|
Diabetes Mellitus, Experimental | 6 | 2021 | 1121 | 0.330 |
Why?
|
Metals | 4 | 2016 | 717 | 0.330 |
Why?
|
Ischemia | 6 | 2022 | 1911 | 0.330 |
Why?
|
Cardiomegaly | 1 | 2011 | 619 | 0.320 |
Why?
|
Prospective Studies | 35 | 2024 | 53187 | 0.320 |
Why?
|
Air Pollutants | 10 | 2014 | 2814 | 0.320 |
Why?
|
Diltiazem | 6 | 2005 | 133 | 0.320 |
Why?
|
Treatment Outcome | 29 | 2022 | 62966 | 0.310 |
Why?
|
Risk Assessment | 22 | 2020 | 23320 | 0.310 |
Why?
|
Calcium Channel Blockers | 7 | 2013 | 689 | 0.310 |
Why?
|
Oxidative Stress | 4 | 2014 | 3081 | 0.300 |
Why?
|
Motor Vehicles | 2 | 2009 | 268 | 0.290 |
Why?
|
Extracellular Matrix | 2 | 2014 | 1740 | 0.290 |
Why?
|
Time Factors | 41 | 2020 | 40054 | 0.290 |
Why?
|
Calcium Signaling | 1 | 2011 | 721 | 0.290 |
Why?
|
Physical Exertion | 7 | 1996 | 695 | 0.290 |
Why?
|
Valine | 1 | 2008 | 413 | 0.280 |
Why?
|
Antioxidants | 2 | 2005 | 1659 | 0.280 |
Why?
|
Circadian Rhythm | 11 | 1997 | 2623 | 0.280 |
Why?
|
Particulate Matter | 6 | 2010 | 2523 | 0.280 |
Why?
|
Hypertension | 8 | 2021 | 8455 | 0.270 |
Why?
|
Aortic Valve | 2 | 2021 | 1911 | 0.270 |
Why?
|
Ventricular Remodeling | 2 | 2010 | 1224 | 0.270 |
Why?
|
Calcinosis | 2 | 2021 | 1497 | 0.270 |
Why?
|
Simvastatin | 1 | 2008 | 360 | 0.270 |
Why?
|
Diabetes Mellitus | 5 | 2018 | 5724 | 0.260 |
Why?
|
Aortic Valve Stenosis | 3 | 2021 | 1941 | 0.260 |
Why?
|
Bioprosthesis | 1 | 2009 | 596 | 0.250 |
Why?
|
Antihypertensive Agents | 2 | 2019 | 2043 | 0.250 |
Why?
|
Blood Pressure | 14 | 2019 | 8541 | 0.250 |
Why?
|
Tomography, X-Ray Computed | 6 | 2023 | 20086 | 0.250 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2007 | 689 | 0.240 |
Why?
|
Cardiac Imaging Techniques | 2 | 2017 | 269 | 0.240 |
Why?
|
Ascorbic Acid | 2 | 2005 | 647 | 0.240 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2006 | 641 | 0.240 |
Why?
|
Carbon | 3 | 2009 | 686 | 0.230 |
Why?
|
Propranolol | 5 | 1993 | 502 | 0.230 |
Why?
|
Swine | 8 | 2020 | 5934 | 0.220 |
Why?
|
Double-Blind Method | 19 | 2017 | 12017 | 0.220 |
Why?
|
Atenolol | 4 | 2000 | 100 | 0.220 |
Why?
|
Vitamin E | 2 | 2005 | 869 | 0.220 |
Why?
|
Occupational Diseases | 1 | 2011 | 1472 | 0.220 |
Why?
|
Tetrazoles | 1 | 2008 | 835 | 0.220 |
Why?
|
Benchmarking | 2 | 2019 | 1038 | 0.220 |
Why?
|
Myocytes, Cardiac | 1 | 2011 | 1636 | 0.210 |
Why?
|
Carotid Artery Diseases | 2 | 2021 | 882 | 0.210 |
Why?
|
Ultrasonography | 6 | 2016 | 5978 | 0.210 |
Why?
|
Heart Valve Prosthesis | 2 | 2009 | 1486 | 0.210 |
Why?
|
Cardiovascular Agents | 5 | 2017 | 848 | 0.200 |
Why?
|
Random Allocation | 12 | 2018 | 2425 | 0.200 |
Why?
|
Prognosis | 30 | 2020 | 29010 | 0.200 |
Why?
|
Japan | 2 | 2016 | 1360 | 0.200 |
Why?
|
Food, Formulated | 1 | 2002 | 109 | 0.200 |
Why?
|
Stroke | 2 | 2023 | 9963 | 0.200 |
Why?
|
Heart | 5 | 2023 | 4462 | 0.190 |
Why?
|
Carotid Arteries | 3 | 2016 | 952 | 0.190 |
Why?
|
Vasodilation | 4 | 2015 | 944 | 0.190 |
Why?
|
Syndrome | 5 | 2021 | 3248 | 0.190 |
Why?
|
Death, Sudden | 5 | 1990 | 298 | 0.190 |
Why?
|
Brachial Artery | 3 | 2015 | 370 | 0.190 |
Why?
|
Dyslipidemias | 2 | 2019 | 848 | 0.180 |
Why?
|
Membrane Glycoproteins | 1 | 2011 | 3769 | 0.180 |
Why?
|
Drug Therapy, Combination | 15 | 2015 | 6483 | 0.180 |
Why?
|
Severity of Illness Index | 14 | 2021 | 15530 | 0.180 |
Why?
|
C-Reactive Protein | 5 | 2010 | 3766 | 0.180 |
Why?
|
Coronary Vasospasm | 4 | 1983 | 88 | 0.180 |
Why?
|
Cardiovascular Diseases | 9 | 2007 | 15108 | 0.180 |
Why?
|
DNA-Activated Protein Kinase | 1 | 2020 | 117 | 0.180 |
Why?
|
Fibrinolytic Agents | 4 | 2006 | 2156 | 0.180 |
Why?
|
Prosthesis Failure | 2 | 2019 | 1203 | 0.180 |
Why?
|
Inflammation | 6 | 2022 | 10578 | 0.180 |
Why?
|
Prosthesis Design | 3 | 2019 | 2110 | 0.170 |
Why?
|
Nitroglycerin | 5 | 2006 | 325 | 0.170 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2015 | 3067 | 0.170 |
Why?
|
Hypercholesterolemia | 3 | 2021 | 1149 | 0.170 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2009 | 1527 | 0.170 |
Why?
|
Cardiotonic Agents | 1 | 2002 | 535 | 0.160 |
Why?
|
Animals | 21 | 2021 | 168561 | 0.160 |
Why?
|
Lipids | 5 | 2022 | 3302 | 0.160 |
Why?
|
Receptors, LDL | 1 | 2020 | 475 | 0.160 |
Why?
|
Arginine | 1 | 2002 | 944 | 0.160 |
Why?
|
Triglycerides | 5 | 2020 | 2450 | 0.160 |
Why?
|
Nadolol | 2 | 1994 | 30 | 0.150 |
Why?
|
Thrombolytic Therapy | 6 | 2002 | 2161 | 0.150 |
Why?
|
Cross-Over Studies | 4 | 2017 | 2030 | 0.150 |
Why?
|
Vascular Resistance | 2 | 2013 | 936 | 0.150 |
Why?
|
Activities of Daily Living | 3 | 1999 | 2414 | 0.150 |
Why?
|
Lipoproteins, LDL | 2 | 2014 | 628 | 0.150 |
Why?
|
Pilot Projects | 11 | 2017 | 8297 | 0.150 |
Why?
|
Sus scrofa | 3 | 2021 | 437 | 0.140 |
Why?
|
Europe | 3 | 2018 | 3339 | 0.140 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2021 | 11695 | 0.140 |
Why?
|
Lipid Metabolism | 1 | 2005 | 1887 | 0.140 |
Why?
|
Sirolimus | 2 | 2016 | 1562 | 0.140 |
Why?
|
Cheyne-Stokes Respiration | 1 | 2016 | 38 | 0.140 |
Why?
|
Arousal | 3 | 1999 | 1165 | 0.140 |
Why?
|
Telemetry | 1 | 2017 | 205 | 0.130 |
Why?
|
Coronary Artery Bypass | 7 | 2001 | 2281 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2020 | 1284 | 0.130 |
Why?
|
Follow-Up Studies | 20 | 2018 | 39004 | 0.130 |
Why?
|
Sleep Apnea, Central | 1 | 2016 | 84 | 0.130 |
Why?
|
Blood Glucose | 2 | 2020 | 6249 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 11 | 2019 | 9941 | 0.130 |
Why?
|
Indocyanine Green | 1 | 2016 | 238 | 0.120 |
Why?
|
Hemorheology | 2 | 2007 | 145 | 0.120 |
Why?
|
Spectroscopy, Near-Infrared | 2 | 2017 | 721 | 0.120 |
Why?
|
Mechanotransduction, Cellular | 1 | 2019 | 541 | 0.120 |
Why?
|
Thrombophilia | 2 | 2015 | 305 | 0.120 |
Why?
|
Angina Pectoris, Variant | 5 | 2002 | 55 | 0.120 |
Why?
|
Pravastatin | 3 | 2015 | 395 | 0.120 |
Why?
|
Heart Conduction System | 3 | 2009 | 1048 | 0.120 |
Why?
|
Rest | 2 | 1997 | 900 | 0.110 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2013 | 1517 | 0.110 |
Why?
|
Hyperlipidemias | 3 | 2015 | 786 | 0.110 |
Why?
|
Mental Processes | 1 | 1994 | 249 | 0.110 |
Why?
|
Data Interpretation, Statistical | 1 | 2023 | 2714 | 0.110 |
Why?
|
Adult | 37 | 2020 | 213712 | 0.110 |
Why?
|
Hypolipidemic Agents | 3 | 2005 | 604 | 0.110 |
Why?
|
Logistic Models | 9 | 2016 | 13403 | 0.110 |
Why?
|
Galvanic Skin Response | 1 | 1994 | 349 | 0.110 |
Why?
|
Aged, 80 and over | 18 | 2021 | 57683 | 0.110 |
Why?
|
Muscle, Smooth, Vascular | 2 | 2013 | 1504 | 0.100 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2015 | 361 | 0.100 |
Why?
|
NF-kappa B | 1 | 2020 | 2500 | 0.100 |
Why?
|
Creatine Kinase | 10 | 1989 | 694 | 0.100 |
Why?
|
Blood Volume | 1 | 2013 | 565 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2016 | 1184 | 0.100 |
Why?
|
Life Support Systems | 1 | 2010 | 11 | 0.100 |
Why?
|
Cathepsin K | 1 | 2011 | 68 | 0.100 |
Why?
|
Cholesterol, HDL | 5 | 2007 | 1813 | 0.100 |
Why?
|
Diastole | 4 | 2017 | 791 | 0.100 |
Why?
|
Ventricular Dysfunction, Left | 2 | 1999 | 2059 | 0.100 |
Why?
|
Pyridines | 4 | 1983 | 2818 | 0.100 |
Why?
|
Particle Size | 5 | 2009 | 1640 | 0.090 |
Why?
|
Enzyme Induction | 1 | 2011 | 475 | 0.090 |
Why?
|
Constriction, Pathologic | 3 | 2023 | 1095 | 0.090 |
Why?
|
Vascular Patency | 2 | 2003 | 885 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2906 | 0.090 |
Why?
|
Fibrosis | 3 | 2018 | 2026 | 0.090 |
Why?
|
Treatment Failure | 3 | 2002 | 2615 | 0.090 |
Why?
|
Anticoagulants | 2 | 2003 | 4595 | 0.090 |
Why?
|
Hypoxia, Brain | 1 | 2010 | 133 | 0.090 |
Why?
|
Clinical Trials as Topic | 11 | 2013 | 7901 | 0.090 |
Why?
|
Dental Care for Disabled | 1 | 1989 | 20 | 0.090 |
Why?
|
Cathepsins | 1 | 2011 | 239 | 0.090 |
Why?
|
DNA Damage | 1 | 2020 | 2423 | 0.090 |
Why?
|
Uric Acid | 1 | 2015 | 760 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2010 | 10943 | 0.090 |
Why?
|
Environmental Exposure | 3 | 2014 | 4231 | 0.090 |
Why?
|
Ticlopidine | 1 | 2015 | 899 | 0.090 |
Why?
|
Sex Factors | 10 | 2020 | 10392 | 0.090 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2021 | 2195 | 0.090 |
Why?
|
Cardiology | 1 | 2020 | 1658 | 0.090 |
Why?
|
Nitrates | 3 | 2006 | 265 | 0.090 |
Why?
|
Glucuronidase | 1 | 2010 | 207 | 0.080 |
Why?
|
Heparin | 3 | 2006 | 1636 | 0.080 |
Why?
|
Patient Selection | 2 | 2010 | 4214 | 0.080 |
Why?
|
Multivariate Analysis | 7 | 2018 | 12242 | 0.080 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2013 | 686 | 0.080 |
Why?
|
Monitoring, Physiologic | 4 | 2010 | 1737 | 0.080 |
Why?
|
Metoprolol | 1 | 1989 | 93 | 0.080 |
Why?
|
Tunica Intima | 1 | 2011 | 464 | 0.080 |
Why?
|
Workload | 2 | 2004 | 849 | 0.080 |
Why?
|
Platelet Aggregation | 2 | 1989 | 800 | 0.080 |
Why?
|
Fluorescent Dyes | 1 | 2016 | 1915 | 0.080 |
Why?
|
Calcium | 1 | 2021 | 5753 | 0.080 |
Why?
|
Radionuclide Imaging | 3 | 2011 | 2027 | 0.080 |
Why?
|
Hydrodynamics | 2 | 2020 | 158 | 0.080 |
Why?
|
Arteriosclerosis | 3 | 2003 | 1092 | 0.080 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2016 | 8925 | 0.080 |
Why?
|
Recurrence | 11 | 2019 | 8333 | 0.080 |
Why?
|
Calcium Channels | 1 | 2011 | 621 | 0.080 |
Why?
|
Disease Models, Animal | 4 | 2016 | 18006 | 0.080 |
Why?
|
Maximum Allowable Concentration | 1 | 2007 | 62 | 0.080 |
Why?
|
Ventricular Function, Left | 3 | 2017 | 3656 | 0.080 |
Why?
|
Linear Models | 4 | 2018 | 5948 | 0.070 |
Why?
|
Death, Sudden, Cardiac | 4 | 2020 | 1541 | 0.070 |
Why?
|
Nitric Oxide | 2 | 2007 | 2128 | 0.070 |
Why?
|
Counterpulsation | 1 | 2006 | 19 | 0.070 |
Why?
|
Aspirin | 2 | 2015 | 3278 | 0.070 |
Why?
|
Autonomic Nervous System | 2 | 2006 | 671 | 0.070 |
Why?
|
Helminth Proteins | 1 | 2007 | 171 | 0.070 |
Why?
|
Cholesterol | 2 | 1995 | 2895 | 0.070 |
Why?
|
Medical Errors | 2 | 2005 | 1296 | 0.070 |
Why?
|
Retrospective Studies | 12 | 2023 | 77098 | 0.070 |
Why?
|
Republic of Korea | 2 | 2018 | 538 | 0.070 |
Why?
|
Thrombosis | 2 | 2019 | 2966 | 0.070 |
Why?
|
Case-Control Studies | 6 | 2022 | 21719 | 0.070 |
Why?
|
Plasminogen Activators | 2 | 1997 | 209 | 0.070 |
Why?
|
Dietary Fats | 2 | 2011 | 2017 | 0.070 |
Why?
|
Mechanoreceptors | 1 | 2007 | 186 | 0.070 |
Why?
|
Elastic Tissue | 1 | 2005 | 65 | 0.070 |
Why?
|
Medical History Taking | 1 | 1989 | 783 | 0.070 |
Why?
|
Hypothermia, Induced | 1 | 2010 | 747 | 0.070 |
Why?
|
Ventricular Dysfunction | 1 | 2006 | 143 | 0.070 |
Why?
|
Endocarditis, Bacterial | 1 | 1989 | 453 | 0.060 |
Why?
|
Therapeutics | 1 | 2005 | 116 | 0.060 |
Why?
|
North America | 2 | 2018 | 1249 | 0.060 |
Why?
|
Isoenzymes | 10 | 1989 | 1725 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9410 | 0.060 |
Why?
|
Exercise Tolerance | 2 | 2017 | 770 | 0.060 |
Why?
|
Odds Ratio | 2 | 2015 | 9846 | 0.060 |
Why?
|
Cohort Studies | 9 | 2022 | 40450 | 0.060 |
Why?
|
Vasomotor System | 1 | 2005 | 209 | 0.060 |
Why?
|
Automobile Driving | 1 | 2009 | 431 | 0.060 |
Why?
|
Air Pollutants, Occupational | 1 | 2006 | 408 | 0.060 |
Why?
|
Sympathetic Nervous System | 1 | 1987 | 514 | 0.060 |
Why?
|
Brazil | 2 | 2018 | 1263 | 0.060 |
Why?
|
Personnel Staffing and Scheduling | 2 | 2004 | 501 | 0.060 |
Why?
|
Diet Therapy | 1 | 2005 | 154 | 0.060 |
Why?
|
Enoxaparin | 1 | 2006 | 377 | 0.060 |
Why?
|
United States | 9 | 2022 | 69693 | 0.060 |
Why?
|
Internationality | 2 | 2021 | 1002 | 0.060 |
Why?
|
Work Schedule Tolerance | 2 | 2004 | 565 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 4147 | 0.060 |
Why?
|
Antithrombins | 1 | 2006 | 304 | 0.060 |
Why?
|
Blood Viscosity | 1 | 2003 | 124 | 0.060 |
Why?
|
Heart Arrest | 2 | 2010 | 1469 | 0.060 |
Why?
|
Thromboembolism | 1 | 2009 | 983 | 0.060 |
Why?
|
Environmental Monitoring | 2 | 2010 | 1413 | 0.060 |
Why?
|
Angiotensins | 1 | 2023 | 151 | 0.060 |
Why?
|
Risk | 6 | 2008 | 9679 | 0.050 |
Why?
|
Diabetes Complications | 2 | 1989 | 1359 | 0.050 |
Why?
|
Postoperative Hemorrhage | 1 | 2006 | 409 | 0.050 |
Why?
|
Body Mass Index | 2 | 2019 | 12695 | 0.050 |
Why?
|
Hemorrhage | 2 | 2009 | 3461 | 0.050 |
Why?
|
Chronic Disease | 4 | 2006 | 9144 | 0.050 |
Why?
|
Age Factors | 9 | 2020 | 18355 | 0.050 |
Why?
|
Dust | 1 | 2005 | 479 | 0.050 |
Why?
|
Necrosis | 2 | 2018 | 1643 | 0.050 |
Why?
|
Organotechnetium Compounds | 1 | 2002 | 137 | 0.050 |
Why?
|
Carbon Monoxide | 1 | 2005 | 531 | 0.050 |
Why?
|
Iatrogenic Disease | 1 | 2005 | 545 | 0.050 |
Why?
|
Verapamil | 2 | 2000 | 244 | 0.050 |
Why?
|
Lovastatin | 1 | 2002 | 120 | 0.050 |
Why?
|
Rabbits | 1 | 2008 | 4886 | 0.050 |
Why?
|
Risk Management | 1 | 2005 | 571 | 0.050 |
Why?
|
Reproducibility of Results | 5 | 2020 | 19862 | 0.050 |
Why?
|
Boston | 6 | 2017 | 9305 | 0.050 |
Why?
|
Renin | 1 | 2023 | 642 | 0.050 |
Why?
|
Acute Disease | 4 | 2006 | 7141 | 0.050 |
Why?
|
Hostility | 1 | 2022 | 189 | 0.050 |
Why?
|
Organophosphorus Compounds | 1 | 2002 | 215 | 0.050 |
Why?
|
Attention | 2 | 2004 | 2396 | 0.050 |
Why?
|
Chronotherapy | 1 | 2000 | 10 | 0.050 |
Why?
|
Systole | 2 | 2004 | 956 | 0.050 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2022 | 314 | 0.050 |
Why?
|
Defibrillators, Implantable | 1 | 2009 | 1440 | 0.040 |
Why?
|
Clinical Protocols | 2 | 2019 | 1459 | 0.040 |
Why?
|
Tissue Plasminogen Activator | 2 | 1997 | 1262 | 0.040 |
Why?
|
Practice Guidelines as Topic | 4 | 2010 | 7276 | 0.040 |
Why?
|
Radionuclide Ventriculography | 1 | 1999 | 41 | 0.040 |
Why?
|
Phenotype | 2 | 2017 | 16331 | 0.040 |
Why?
|
Body Surface Area | 1 | 2020 | 198 | 0.040 |
Why?
|
Anger | 1 | 2022 | 402 | 0.040 |
Why?
|
Thallium Radioisotopes | 1 | 1999 | 139 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2000 | 388 | 0.040 |
Why?
|
Longitudinal Studies | 4 | 2019 | 13921 | 0.040 |
Why?
|
MicroRNAs | 1 | 2015 | 3731 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2023 | 759 | 0.040 |
Why?
|
Aldosterone | 1 | 2023 | 876 | 0.040 |
Why?
|
Biology | 1 | 2020 | 292 | 0.040 |
Why?
|
Regeneration | 1 | 2007 | 1485 | 0.040 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2007 | 997 | 0.040 |
Why?
|
Survival Rate | 6 | 2010 | 12773 | 0.040 |
Why?
|
Multicenter Studies as Topic | 5 | 2006 | 1661 | 0.040 |
Why?
|
Intensive Care Units | 3 | 2005 | 3679 | 0.040 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2010 | 3328 | 0.040 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2005 | 1538 | 0.040 |
Why?
|
Anxiety | 2 | 2009 | 4279 | 0.040 |
Why?
|
Atrial Fibrillation | 1 | 2016 | 5019 | 0.040 |
Why?
|
Counseling | 1 | 2005 | 1521 | 0.040 |
Why?
|
Autonomic Nervous System Diseases | 2 | 2010 | 257 | 0.040 |
Why?
|
Heart Failure | 7 | 2008 | 10856 | 0.040 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 1107 | 0.040 |
Why?
|
Heart Diseases | 2 | 2006 | 2789 | 0.040 |
Why?
|
Absorbable Implants | 1 | 2019 | 342 | 0.040 |
Why?
|
Cardiomyopathies | 1 | 2008 | 1912 | 0.040 |
Why?
|
Occupational Exposure | 1 | 2006 | 1794 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2020 | 977 | 0.030 |
Why?
|
Catecholamines | 1 | 1996 | 387 | 0.030 |
Why?
|
Oscillometry | 1 | 2016 | 147 | 0.030 |
Why?
|
HLA Antigens | 1 | 1981 | 1382 | 0.030 |
Why?
|
Cholestyramine Resin | 1 | 1994 | 24 | 0.030 |
Why?
|
Gemfibrozil | 1 | 1994 | 30 | 0.030 |
Why?
|
Problem Solving | 1 | 1998 | 440 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2020 | 14554 | 0.030 |
Why?
|
Life Style | 1 | 2006 | 3824 | 0.030 |
Why?
|
Oxygen | 1 | 2006 | 4169 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2303 | 0.030 |
Why?
|
Combined Modality Therapy | 4 | 1996 | 8621 | 0.030 |
Why?
|
Sex Characteristics | 2 | 2020 | 2585 | 0.030 |
Why?
|
Internship and Residency | 2 | 2004 | 5774 | 0.030 |
Why?
|
Incidence | 3 | 2009 | 20928 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2016 | 1420 | 0.030 |
Why?
|
Peptides | 1 | 2006 | 4392 | 0.030 |
Why?
|
Heart Atria | 1 | 2020 | 1348 | 0.030 |
Why?
|
Platelet Function Tests | 1 | 2015 | 270 | 0.030 |
Why?
|
Niacin | 1 | 1994 | 116 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2020 | 1157 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2006 | 5095 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 493 | 0.030 |
Why?
|
Drug Administration Schedule | 3 | 2007 | 4929 | 0.030 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2003 | 1384 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2003 | 5062 | 0.030 |
Why?
|
Thermodilution | 1 | 2013 | 51 | 0.030 |
Why?
|
Shock, Cardiogenic | 2 | 1989 | 684 | 0.030 |
Why?
|
Kidney | 2 | 2021 | 7167 | 0.030 |
Why?
|
Humidity | 1 | 2014 | 197 | 0.030 |
Why?
|
Heart Murmurs | 2 | 1990 | 94 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2003 | 2266 | 0.030 |
Why?
|
Protein Kinases | 1 | 2020 | 1638 | 0.030 |
Why?
|
Aorta | 1 | 2020 | 2057 | 0.030 |
Why?
|
Consensus | 2 | 2017 | 2935 | 0.030 |
Why?
|
Fluorescein Angiography | 1 | 2017 | 936 | 0.030 |
Why?
|
Adipose Tissue | 2 | 2022 | 3278 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2021 | 1707 | 0.030 |
Why?
|
Depression | 2 | 2009 | 7733 | 0.030 |
Why?
|
Comorbidity | 3 | 2016 | 10372 | 0.030 |
Why?
|
Statistics as Topic | 2 | 1996 | 2372 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 14720 | 0.030 |
Why?
|
Heart Ventricles | 4 | 2020 | 3801 | 0.030 |
Why?
|
Decision Support Techniques | 1 | 2002 | 1952 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2018 | 3510 | 0.030 |
Why?
|
Seasons | 2 | 2014 | 1492 | 0.030 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2017 | 555 | 0.020 |
Why?
|
Clinical Enzyme Tests | 2 | 1988 | 115 | 0.020 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 3038 | 0.020 |
Why?
|
Ambulatory Care | 3 | 1994 | 2706 | 0.020 |
Why?
|
Cost of Illness | 1 | 2021 | 1852 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1653 | 0.020 |
Why?
|
Drug Synergism | 1 | 2015 | 1791 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2000 | 1788 | 0.020 |
Why?
|
Exercise | 3 | 2021 | 5611 | 0.020 |
Why?
|
Heparan Sulfate Proteoglycans | 1 | 2010 | 118 | 0.020 |
Why?
|
Sleep Deprivation | 3 | 2004 | 830 | 0.020 |
Why?
|
Obesity | 2 | 2015 | 12705 | 0.020 |
Why?
|
Manifest Anxiety Scale | 1 | 2009 | 8 | 0.020 |
Why?
|
Hospitalization | 8 | 2008 | 10232 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 2021 | 12071 | 0.020 |
Why?
|
Analysis of Variance | 4 | 1995 | 6365 | 0.020 |
Why?
|
False Negative Reactions | 3 | 1988 | 587 | 0.020 |
Why?
|
Heart Rupture | 1 | 1989 | 23 | 0.020 |
Why?
|
Heart Rupture, Post-Infarction | 1 | 1989 | 49 | 0.020 |
Why?
|
Algorithms | 3 | 2020 | 13853 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2002 | 3294 | 0.020 |
Why?
|
Sleep | 1 | 2004 | 4604 | 0.020 |
Why?
|
Evaluation Studies as Topic | 2 | 1988 | 1676 | 0.020 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2010 | 472 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 1988 | 377 | 0.020 |
Why?
|
False Positive Reactions | 3 | 1988 | 981 | 0.020 |
Why?
|
Rheumatic Heart Disease | 1 | 1989 | 177 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 2167 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1794 | 0.020 |
Why?
|
Cell Movement | 1 | 2020 | 5212 | 0.020 |
Why?
|
Mitral Valve Prolapse | 1 | 1989 | 230 | 0.020 |
Why?
|
Signal Transduction | 2 | 2021 | 23387 | 0.020 |
Why?
|
ROC Curve | 1 | 2015 | 3528 | 0.020 |
Why?
|
Pericarditis | 1 | 1989 | 128 | 0.020 |
Why?
|
Internal Medicine | 2 | 2004 | 1009 | 0.020 |
Why?
|
Reference Values | 1 | 1994 | 4982 | 0.020 |
Why?
|
Stroke Volume | 6 | 1991 | 4983 | 0.020 |
Why?
|
Temperature | 1 | 2014 | 2207 | 0.020 |
Why?
|
Age of Onset | 1 | 1994 | 3266 | 0.020 |
Why?
|
Missouri | 1 | 2007 | 116 | 0.020 |
Why?
|
Coma | 1 | 2010 | 475 | 0.020 |
Why?
|
Recombinant Proteins | 2 | 2007 | 6608 | 0.020 |
Why?
|
Recovery of Function | 1 | 2017 | 2924 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 1999 | 12958 | 0.020 |
Why?
|
Prevalence | 3 | 2018 | 15194 | 0.020 |
Why?
|
Personality Inventory | 1 | 2009 | 1026 | 0.020 |
Why?
|
Bundle-Branch Block | 1 | 1988 | 270 | 0.020 |
Why?
|
Evidence-Based Practice | 1 | 2010 | 500 | 0.020 |
Why?
|
Sulfur Dioxide | 1 | 2006 | 177 | 0.020 |
Why?
|
Welding | 1 | 2006 | 89 | 0.020 |
Why?
|
Death Certificates | 1 | 1987 | 169 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5655 | 0.020 |
Why?
|
Ohio | 1 | 2006 | 337 | 0.020 |
Why?
|
Fatty Acids, Omega-3 | 1 | 1995 | 1341 | 0.020 |
Why?
|
Digoxin | 1 | 1986 | 250 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2010 | 1213 | 0.020 |
Why?
|
Hirudins | 1 | 2006 | 182 | 0.020 |
Why?
|
Soot | 1 | 2007 | 232 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2002 | 5133 | 0.020 |
Why?
|
Educational Status | 1 | 1993 | 2533 | 0.020 |
Why?
|
Meteorological Concepts | 1 | 2004 | 30 | 0.020 |
Why?
|
Women | 1 | 1987 | 230 | 0.020 |
Why?
|
Tachycardia | 1 | 1987 | 620 | 0.020 |
Why?
|
Societies, Medical | 1 | 2017 | 3740 | 0.020 |
Why?
|
Truth Disclosure | 1 | 2009 | 435 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2007 | 891 | 0.020 |
Why?
|
Ventricular Fibrillation | 1 | 1987 | 538 | 0.020 |
Why?
|
Sinoatrial Node | 1 | 1985 | 101 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 1997 | 12344 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2010 | 950 | 0.020 |
Why?
|
Heart Block | 1 | 1986 | 410 | 0.020 |
Why?
|
Echocardiography | 1 | 2017 | 5097 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3151 | 0.020 |
Why?
|
Benzofurans | 1 | 1985 | 140 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 10472 | 0.010 |
Why?
|
Adaptation, Physiological | 1 | 2010 | 1310 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8425 | 0.010 |
Why?
|
Nitrogen Dioxide | 1 | 2006 | 490 | 0.010 |
Why?
|
Disability Evaluation | 1 | 1991 | 1827 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2009 | 2970 | 0.010 |
Why?
|
African Americans | 1 | 2002 | 23 | 0.010 |
Why?
|
Oxygen Consumption | 1 | 1990 | 1869 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81045 | 0.010 |
Why?
|
Amiodarone | 1 | 1985 | 212 | 0.010 |
Why?
|
Self-Assessment | 1 | 2005 | 390 | 0.010 |
Why?
|
Psychological Tests | 1 | 2005 | 648 | 0.010 |
Why?
|
Smoking | 3 | 2015 | 8969 | 0.010 |
Why?
|
Ozone | 1 | 2006 | 469 | 0.010 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2010 | 974 | 0.010 |
Why?
|
Bronchodilator Agents | 1 | 2006 | 502 | 0.010 |
Why?
|
Benzazepines | 1 | 1985 | 326 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2007 | 2271 | 0.010 |
Why?
|
Hypotension | 2 | 1986 | 880 | 0.010 |
Why?
|
Probability | 2 | 1987 | 2502 | 0.010 |
Why?
|
Air Pollution, Indoor | 1 | 2009 | 855 | 0.010 |
Why?
|
Cerebrovascular Disorders | 1 | 1989 | 1499 | 0.010 |
Why?
|
Vasoconstriction | 1 | 2004 | 596 | 0.010 |
Why?
|
Melatonin | 1 | 2007 | 720 | 0.010 |
Why?
|
Substance Withdrawal Syndrome | 1 | 1986 | 633 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2010 | 1889 | 0.010 |
Why?
|
Forced Expiratory Volume | 1 | 2006 | 1741 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6259 | 0.010 |
Why?
|
Coronary Care Units | 1 | 1982 | 214 | 0.010 |
Why?
|
Genotype | 1 | 2015 | 12946 | 0.010 |
Why?
|
Quality of Life | 1 | 2002 | 12730 | 0.010 |
Why?
|
Mitral Valve Insufficiency | 1 | 1990 | 1415 | 0.010 |
Why?
|
Remission Induction | 2 | 1995 | 2384 | 0.010 |
Why?
|
Twins | 1 | 1981 | 339 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2005 | 2885 | 0.010 |
Why?
|
Postoperative Complications | 2 | 2015 | 15244 | 0.010 |
Why?
|
Medication Errors | 1 | 2005 | 797 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2005 | 2536 | 0.010 |
Why?
|
Vascular Diseases | 1 | 2006 | 1155 | 0.010 |
Why?
|
Polysomnography | 1 | 2004 | 1772 | 0.010 |
Why?
|
Myocardium | 3 | 2003 | 4775 | 0.010 |
Why?
|
Exercise Therapy | 1 | 2004 | 904 | 0.010 |
Why?
|
Troponin I | 1 | 2001 | 619 | 0.010 |
Why?
|
Canada | 1 | 2002 | 2061 | 0.010 |
Why?
|
Placebos | 2 | 1996 | 1677 | 0.010 |
Why?
|
Delayed-Action Preparations | 1 | 2000 | 965 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2003 | 1780 | 0.010 |
Why?
|
Health Surveys | 1 | 2006 | 4030 | 0.010 |
Why?
|
Clostridium perfringens | 1 | 1976 | 27 | 0.010 |
Why?
|
Terminology as Topic | 1 | 2003 | 1548 | 0.010 |
Why?
|
Phospholipases | 1 | 1976 | 72 | 0.010 |
Why?
|
Diphosphates | 2 | 1986 | 88 | 0.010 |
Why?
|
Isosorbide Dinitrate | 1 | 1994 | 34 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 1986 | 1914 | 0.010 |
Why?
|
Insulin | 1 | 1989 | 6575 | 0.010 |
Why?
|
Plant Oils | 1 | 1995 | 202 | 0.010 |
Why?
|
Adolescent | 3 | 2007 | 85649 | 0.010 |
Why?
|
Norepinephrine | 1 | 1996 | 909 | 0.010 |
Why?
|
Information Systems | 1 | 1996 | 410 | 0.010 |
Why?
|
Dietary Fats, Unsaturated | 1 | 1995 | 226 | 0.010 |
Why?
|
Massachusetts | 1 | 1987 | 8662 | 0.010 |
Why?
|
Epinephrine | 1 | 1996 | 793 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1981 | 4742 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2002 | 2658 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2003 | 5385 | 0.010 |
Why?
|
Lipoproteins | 1 | 1995 | 876 | 0.010 |
Why?
|
Health Care Costs | 1 | 2003 | 3203 | 0.010 |
Why?
|
Clostridium Infections | 1 | 1976 | 548 | 0.010 |
Why?
|
Heart Septum | 1 | 1989 | 313 | 0.000 |
Why?
|
Mass Screening | 1 | 2003 | 5238 | 0.000 |
Why?
|
Survival Analysis | 1 | 2000 | 10248 | 0.000 |
Why?
|
Fatty Acids | 1 | 1995 | 1806 | 0.000 |
Why?
|
Heart Function Tests | 1 | 1987 | 330 | 0.000 |
Why?
|
Technetium Tc 99m Pyrophosphate | 1 | 1986 | 44 | 0.000 |
Why?
|
Technetium | 1 | 1986 | 334 | 0.000 |
Why?
|
Reoperation | 1 | 1995 | 4200 | 0.000 |
Why?
|
Bradycardia | 1 | 1986 | 305 | 0.000 |
Why?
|
Eating | 1 | 1990 | 1535 | 0.000 |
Why?
|
Regression Analysis | 1 | 1992 | 6452 | 0.000 |
Why?
|
Sepsis | 1 | 1976 | 2589 | 0.000 |
Why?
|
Patient Readmission | 1 | 1995 | 3111 | 0.000 |
Why?
|
Databases, Factual | 1 | 1996 | 7716 | 0.000 |
Why?
|
Drug Interactions | 1 | 1985 | 1458 | 0.000 |
Why?
|
Myocardial Contraction | 1 | 1985 | 1585 | 0.000 |
Why?
|
Pregnancy | 1 | 1981 | 29087 | 0.000 |
Why?
|
Kidney Diseases | 1 | 1988 | 2145 | 0.000 |
Why?
|
Chromatography, Thin Layer | 1 | 1976 | 223 | 0.000 |
Why?
|
Diglycerides | 1 | 1976 | 176 | 0.000 |
Why?
|
Anemia, Hemolytic | 1 | 1976 | 168 | 0.000 |
Why?
|
Patient Admission | 1 | 1982 | 1380 | 0.000 |
Why?
|
Anemia, Aplastic | 1 | 1976 | 226 | 0.000 |
Why?
|
Patient Compliance | 1 | 1984 | 2680 | 0.000 |
Why?
|
Length of Stay | 1 | 1982 | 6294 | 0.000 |
Why?
|